New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

March 2014

Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe

Press Releases / By

CRANBURY, N.J., March 31, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for …

Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe Read More »

Palatin Technologies To Present At The 26Th Annual ROTH Conference

Press Releases / By

CRANBURY, N.J., March 6, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and …

Palatin Technologies To Present At The 26Th Annual ROTH Conference Read More »

Scroll to Top